AstraNu raises $3.5M to shrink optical imaging onto a chip
What's the deal? AstraNu, a New Jersey-based startup developing a chip-scale optical imaging engine, has closed a $3.5 million seed round led by Celesta CapitalDealroom has a profile for this one. Try Dealroom →. The round included matching co-investment from the New Jersey Innovation Evergreen Fund, a program of the New Jersey Economic Development AuthorityDealroom has a profile for this one. Try Dealroom →.
What's the endgame? AstraNu builds a tiny swept-source optical coherence tomography (OCT) imaging engine that medical device, imaging, and optics companies can integrate into their products. It says the technology delivers the performance of larger swept-source OCT systems at roughly one-tenth the size.
"You could take that same technology and put it into something that fits in your hand... We can put it all in a handheld unit," president and general manager Kevin Blalock told MobiHealthNews.
Why now? The company spun out of Nokia Bell LabsDealroom has a profile for this one. Try Dealroom → in May 2025, backed by Celesta, after founders spent roughly 10 years on the technology. Blalock said the funding is pushing AstraNu out of the prototype phase and into development. It will use the capital to expand its photonics team, prepare for volume manufacturing, and validate the imaging engine with application partners.
What's next? AstraNu first demonstrated its technology in middle-ear imaging, but its first commercial focus will be ophthalmology, with other uses being explored in urology, oncology, and ear, nose and throat care.
"We're not a pure medical device company, but we are working with those medical device companies to improve their technology or to create a new product within their portfolio," Blalock said. He expects the company to start selling modules in some volume to partners by mid to late 2027.
What could go wrong? AstraNu remains very early stage, with its success tied to moving from demonstrations to shipping products. Blalock said the team is still maturing its suppliers and supply chain to meet anticipated demand.
The signal: Investors have shown strong appetite for photonics, but most recent capital targets AI data-center interconnects rather than imaging. AstraNu's modest seed is a bet on a distinct application — chip-scale imaging — where significance will hinge on whether the technology reaches practical products and customers, not on the amount alone.
Read more: mobihealthnews.com
Image credit: Generated with Gemini